Opus Genetics stockholders elect nine directors and approve all proposals at 2025 annual meeting

Opus Genetics, Inc.

All nine director nominees elected with >21M votes for each; no withhold votes exceeded 3.1M.
Ratification of Ernst & Young as auditor for FY2025 passed with 30.2M votes for (94% of votes cast).
Advisory say-on-pay proposal approved with 20.4M votes for (86% of votes cast).
Conversion of Series A Preferred Stock into common stock approved with 16.7M votes for (84% of votes cast).
Adjournment proposal passed but deemed moot as Conversion proposal already passed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.